PDCD1 and neoplasm: Most of the PD-1-targeted therapeutic antibodies are IgG4 human or humanized MAbs that block the PD-1/PD-L1 or PD-1/PD-L2 interaction to restore tumor-specific T cell reactivity without mediating antibody-dependent cell-mediated cytotoxicity (ADCC).